Chimioradiothérapie des cancers de l’œsophage : revue critique de la littérature [Chemoradiation for oesophageal cancer: A critical review of the literature]

Details

Serval ID
serval:BIB_3CB618748C66
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Chimioradiothérapie des cancers de l’œsophage : revue critique de la littérature [Chemoradiation for oesophageal cancer: A critical review of the literature]
Journal
Cancer radiotherapie
Author(s)
Blais E., Vendrely V., Sargos P., Créhange G., Huguet F., Maingon P., Simon J.M., Bourdais R., Ozsahin M., Bourhis J., Clément-Colmou K., Belghith B., Proudhom Briois M.A., Gilliot O., Dujols J.P., Peyras A., Dupin C., Riet F.G., Canova C.H., Huertas A., Troussier I.
ISSN
1769-6658 (Electronic)
ISSN-L
1278-3218
Publication state
Published
Issued date
02/2019
Peer-reviewed
Oui
Volume
23
Number
1
Pages
62-72
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Locally advanced oesophageal cancer treatment requires a multidisciplinary approach with the combination of chemotherapy and radiotherapy for preoperative and definitive strategy. Preoperative chemoradiation improves the locoregional control and overall survival after surgery for locally advanced oesophageal cancer. Definitive chemoradiation can also be proposed for non-resectable tumours or medically inoperable patients. Besides, definitive chemoradiation is considered as an alternative option to surgery for locally advanced squamous cell carcinomas. Chemotherapy regimen associated to radiotherapy consists of a combination of platinum derived drugs (cisplatinum or oxaliplatin) and 5-fluorouracil or a weekly scheme combination of carboplatin and paclitaxel according to CROSS protocol in a neoadjuvant strategy. Radiation doses vary from 41.4Gy to 45Gy for a preoperative strategy or 50 to 50.4Gy for a definitive treatment. The high risk of lymphatic spread due to anatomical features could justify the use of an elective nodal irradiation when the estimated risk of microscopic involvement is higher than 15% to 20%. An appropriate delineation of the gross tumour volume requires an exhaustive and up-to-date evaluation of the disease. Intensity-modulated radiation therapy represents a promising approach to spare organs-at-risk. This critical review of the literature underlines the roles of radiotherapy for locally advanced oesophageal cancers and describes doses, volumes of treatment, technical aspects and dose constraints to organs-at-risk.
Keywords
Chemoradiotherapy, Esophageal Neoplasms/pathology, Esophageal Neoplasms/therapy, Humans, Lymph Nodes/radiation effects, Neoadjuvant Therapy, Radiotherapy Dosage, Tumor Burden, Cancer de l’œsophage, Chemoradiation, Chimioradiothérapie, Chimiothérapie, Neoadjuvant therapy, Oesophageal cancer, Radiochemotherapy, Radiochimiothérapie, Radiotherapy, Radiothérapie, Traitement néoadjuvant
Pubmed
Web of science
Create date
08/02/2019 17:29
Last modification date
20/08/2019 13:32
Usage data